BASF and Poietis Sign a Research and Development Agreement
News Jul 11, 2015
BASF and Poietis have signed an agreement on research and development in cosmetics. Based on the combined expertise of both companies in tissue engineering and bioprinting, the agreement aims to apply the bioprinting technology of Poietis to improve BASF’s skin equivalent model Mimeskin™. The terms and conditions of this agreement were not disclosed.
The 3D laser-assisted bioprinting technology, by which organic tissues can be reproduced, allows for a precise positioning of the skin cells in three-dimensional structures. Through this, cells are cultivated within BASF’s skin model Mimeskin™, which is the closest equivalent to the original physiological tissue of human skin.
Dr. Fabien Guillemot, Founder and President of Poietis, remarks: “We are extremely pleased about this collaboration. Having long-term expertise in solutions for the dermocosmetics market, BASF understands the benefits of 3D laser-assisted bioprinting compared to conventional cell culture technologies and other bioprinting methods. The partnership also emphasizes bioprinted tissue models as an alternative to animal testing in cosmetics and dermopharmacy.”
Poietis’ bioprinting technology refines BASF’s skin model Mimeskin™ due to its advanced printing resolution. The laser-assisted bioprinting technology will be used in a first step to allow for automated reproduction of Mimeskin™, followed by more advanced models containing additional cell types.
Dr. Sebastien Cadau, responsible for tissue engineering development at BASF, points out: “Compared to other bioprinting methods the laser-assisted technology provides higher resolution when it comes to the patterning of cells. The partnership with Poietis allows BASF to secure its strategic advantage in better understanding the skin mechanisms which support the development and testing of advanced cosmetic bioactives for skin care applications.”
The spatial and temporal dynamics of proteins or organelles plays a crucial role in controlling various cellular processes and in development of diseases. However, acute control of activity at distinct locations within a cell cannot be achieved. A new chemo-optogenetic method enables tunable, reversible, and rapid control of activity at multiple subcellular compartments within a living cell.
Scientists have used machine learning to train computers to see parts of the cell the human eye cannot easily distinguish. Using 3D images of fluorescently labeled cells, the research team taught computers to find structures inside living cells without fluorescent labels, using only black and white images generated by an inexpensive technique known as brightfield microscopy.READ MORE
3rd International Conference On Agricultural Engineering and Food Security
Nov 12 - Nov 13, 2018
25th International Conference on Advanced Clinical Research and Clinical Trials
Sep 16 - Sep 17, 2019
8th InterAmerican Oncology Conference 'Current Status and Future of Anti-Cancer Therapies'
Oct 17 - Oct 18, 2019